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Gene manipulationThe potential of the minipig as a platform for future developments in genomics, high density biology,
transgenic technology, in vitro toxicology and related emerging technologies was reviewed. Commercial
interests in the pig as an agricultural production species have driven scientiﬁc progress in these areas. There
is no equivalent economic driver for progress in the dog or the monkey. As a result the available knowledge-
bases are much greater for pigs (than for dogs or monkeys) in many areas (physiology, disease, genetics,
immunology etc). Fundamental genomic knowledge and phenotypic characterization in regard to the pig is
well in advance of the dog or the monkey and basic knowledge of the pig is therefore likely to stay ahead of
the other two species. While the emerging technologies are essentially “species neutral” and can in principle
be applied to all species, for all the technologies that we examined, basic knowledge and technical
capabilities are greater for the pig than the dog or monkey. In concrete terms, in application to safety testing
we have seen that: (i) The Göttingen minipig is well positioned for the performance of toxicogenomics
studies, (ii) The close sequence homology between pigs and humans suggest that minipigs will be useful for
the testing of biotechnology products (and possibly for in silico toxicology) and (iii) the minipig is the only
non-rodent toxicology model where transgenic animals can be readily generated, and reproductive
technologies are well developed in the pig. These properties should also make the minipig an interesting
model for the testing of biotechnology products. These factors all support the idea that the minipig is well
placed to meet the challenges of the emerging technologies and the toxicology of the future; it also seems
likely that the minipig can be an advantageous model for the testing of biotechnology products.e authors and not necessarily
33 232678705.
, ancian@transgene.fr
, hsimian@gwdg.de
).
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1.1. Introduction
In this article we review the potential of the minipig as a platform
for future developments in genomics, high density biology, transgenic
technology, in vitro toxicology and related emerging technologies, as a
contribution to the RETHINKproject (Forster, Bode, Ellegaard& van der
Laan 2010a-this issue, 2010b-this issue). The impact of some of these
technologies on toxicology and safety evaluation of new medicines
and chemicals is already evident. We expect that in the coming years,these new technologies will be the drivers for signiﬁcant develop-
ments and changes in theway that we perform safety studies, andwill
provide new tools for safety assessment. It is therefore essential, if the
minipig is to play a role in the safety assessment of the future, that it is
well adapted to these new technologies.
The speciﬁc technologies that were identiﬁed for evaluation by the
authors included biosensors, genomics and toxicogenomics, genetic
manipulation, stem cell technology, manipulation of the immune
system and in vitro toxicology. For each of these topics in this article
we have reviewed the current state-of-the-art with regard to pigs and
minipigs, and the potential for future developments and applications
in this animal model.
1.2. Application of the 3Rs
In what way does this part of the RETHINK project also contribute
to the application of the 3Rs? The evaluation of the minipig as a
platform for emerging technologies in toxicology is a relevant
discussion for the application of the 3Rs for several reasons.
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use of theminipig in toxicity testing, andwe do not therefore expect
to directly address issues of Replacement in this article.
– Technological developments can have a positive impact on
Reﬁnement; an example could be the application of minimally or
non-invasive measuring systems reducing or eliminating the need
for surgery or other interventions. Non-invasive measurements of
this kind can be achieved through the use of transgenic animals
and imaging systems. Furthermore, such approaches may permit
the use of fewer animals in a study (e.g. using time course analysis
from single animals rather than using a set of animals) and may
therefore bring a beneﬁt in terms of Reduction.
– More sophisticated analysis systems such as genomic tools or
multiplex analyses that provide considerably greater and more
detailed outputs of information from single animals in comparison
to current experimental approaches can be expected to result in a
corresponding positive impact in terms of Reduction.
– In most cases the emerging technologies discussed in this article
are neutral in terms of species, and can be equally applied to the
minipig or to dogs, monkeys or other non-rodent animals used in
toxicity testing. Nevertheless, it was repeatedly noted that the
current knowledge base for most of the technologies is signiﬁ-
cantly greater for the pig than the dog or primate. This is true for
genomics, reproductive biology, immunology and genetic manip-
ulation. In terms of future animal use, therefore, there is a potential
beneﬁt in building on the existing well developed porcine
knowledge base and a potential negative impact of using the dog
or primate, since extensive experimentation would be required to
reach the same general state of advancement.
1.3. Origin, history and genetics of the Göttingen minipig
A review of the origins and genetic management of the Göttingen
minipig is presented inanaccompanying article (Simianer&Köhn, 2010-
this issue). The review provides valuable background information both
for the present article, and gives a unique insight into the history of this
animal model. Some important and relevant conclusions emerge from
the accompanying article, including the following:
– The Göttingen minipig is an almost unique resource, since the
entire population history is extremely well documented back to
the early development of the population in the 1960s.
– The genetic management of the entire breeding population of the
Göttingen minipig is assured by the Institute of Animal Breeding
and Genetics of the Georg August University of Göttingen, with
objectives to maintain the genetic integrity and uniformity of the
population, to balance adverse effects of inbreeding and to pursue
desired breeding objectives.
– The proportional dwarﬁsm of the Göttingen minipig is probably
mediated by modulation of the actions of growth hormone and/or
insulin-like growth factor 1 and is not associated with any genetic
defects or disturbances of development.
– The light skin colour of the Göttingen minipig is due to a
“dominant white” genetic status; the molecular basis of this is
not entirely understood (Marklund, Kijas, Rodriguez-Martinez,
Rönnstrand, Funa, Moller et al., 1998). The Göttingen minipig is
not an albino and melanin is present in the skin, and the retina of
Gottingen minipigs is pigmented.
2. Pig structural genomics
In this article questions are addressed such as: what is the current
state-of-the-art with regard to pig genemapping, sequencing, bioinfor-
matics and functional analyses? Can genomic data derived from
domestic/farm pigs be extrapolated to minipigs used as toxicologymodels? What future developments can be foreseen in this area? How
does this compare with the dog, monkey and other toxicology models?
Because of the important economic role of the pigmeat industry
both in Europe and around the world, an enormous amount of basic
and applied animal breeding, genetics and genomics research has
been conducted in the pig. This has led to in-depth characterization of
many phenotypic traits, with particular emphasis on those traits of
importance to sustainable production (growth, feed efﬁciency, meat
quality, fertility, disease-related traits etc.). Understanding of the
genetic basis of these traits, and the genetic prediction of phenotype is
of major economic importance for the pigmeat industry and this has
provided a great incentive to develop new tools to study the pig
genome.
The genome of the pig comprises 18 autosomes, and 2 sex
chromosomes (X and Y). The genome is similar in size to that of
humans and is estimated at 2.7Gb (Gigabases). Through the EU-
supported Pig Gene Mapping Project (PiGMaP, PiGMaP2 and GENET-
PIG, all funded under EC Framework III programmes) and through
research activities in the U.S, the basic tools for studies in pig genomics
have been developed. These tools comprise several thousand micro-
satellitemarkers and carefully built linkagemaps (www.thearkdb.org/
arkdb/; www.marc.usda.gov/genome/swine/swine.html); well char-
acterized radiation hybrid panels (www.toulouse.inra.fr/lgc/pig/RH/
IMpRH.htm); and comparative maps (http://www.toulouse.inra.fr/
lgc/pig/compare/compare.htm). The comparative maps show that
there is extensive conserved homology with the human genome. The
blocks of pig–human synteny are on average larger (Frönicke,
Chowdhary, Scherthan & Gustavsson, 1996) than both the dog–
human and the mouse–human synteny blocks (Breen, Thomas, Binns,
Carter & Langford, 1999; Nilsson, Helou, Walentinsson, Szpirer,
Nerman& Ståhl, 2001), indicating that fewer chromosomal rearrange-
ments have occurred since divergence of the pig and human lineages.
These genetic tools have been used to identify and infer the
functions of individual genes (e.g. Fujii, Otsu, Zorzato, DE Leon,
Khanna, O'Brian et al., 1998; Meijerink, Fries, Voegeli, Masabanda,
Wigger, Stricker et al., 1997; Van Laere, Nguyen, Braunschweig, Nezer,
Collette, Moreau et al., 2003; Jørgensen, Cirera, Anderson, Archibald,
Raudsepp, Chowdhary et al., 2003) and to identify quantitative trait
loci (QTL) of importance to sustainable breeding (see, for example, the
pig QTL database at: www.animalgenome.org/QTLdb/pig.html). Nu-
merous QTL studies have been performed in pigs, with many
concordant results, indicating that there are good possibilities for
correlating phenotypes and genotypes. This will provide new
functional knowledge about gene function and gene interaction.
Whole genome sequences are an important resource in biomedical
research and today genome sequences are available for many species
includinghumans, cattle andmice. Efforts are alsounderway to sequence
the porcine genome. This work is coordinated through the International
Swine Genome Sequencing Consortium (http://piggenome.org/) and
progress on this project can be inspected at thewebsite (www.sanger.ac.
uk/Projects/S_scrofa/ ). As of Spring 2008, ten chromosomes have been
assembled and it is anticipated that the remaining chromosomes will be
assembled soon.
In addition to genomic sequencing, efforts have also been made to
generate sequence information on cDNA. The Sino–Danish Pig
Genome Sequencing Consortium has, for instance, generated approx-
imately 1 million porcine EST's (Expressed Sequence Tags) (Gorodkin,
Cirera, Gilchrist, Paniz, Jørgensen, Scheiby-Knudsen et al., 2007).
Parallel to the generation of more sequence information, oligo arrays
have been developed for commercialisation by Affymetrix and Qiagen,
permitting gene expression studies as described below.
Genotyping arrays with Single Nucleotide Polymorphisms (SNPs)
have also been established. The ﬁrst porcine SNP chip has been
developedwithin the context of the EU SABRE project. Thismicroarray
contains 7.5 K informative SNPs on an Illumina chip (the porcine SNP
chip is not commercially available).Within the coming 6–12 months it
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full characterization of theminipig genome and provide genotyping at
the “individual animal” level.
New developments in sequencing technologies are transforming
this ﬁeld and opening up possibilities for even more rapid progress in
genomics. New low-cost high-throughput techniques based on
pyrosequencing chemistry (commercialised by Solexa and 454 Life
Sciences) make it possible to perform resequencing at a very high
scale. This should increase our ability to make a direct connection
between information on phenotype and information about the genes
underlying the phenotype in question. In future gene mapping
projects the outcome will not only be identiﬁcation of candidate
regions, as is often the case now, but rather identiﬁcation of the actual
genes and molecular mechanisms underlying the traits in question.
2.1. Applicability of pig genomics mapping and tools to the minipig
The various tools and resources established for research in genomics
outlined in the previous section are applicable to all pig breeds including
minipigs. This point has been amply demonstrated by studies in pig
resource populations produced by crossing divergent breeds (e.g.
Andersson, Haley, Ellegren, Knott, Johansson, Andersson et al., 1994;
SanCristobal, Chevalet, Haley, Joosten, Rattink, Harlizius et al., 2006).
Apredominant feature of thepig as a biomedicalmodel is that because
of its economic and agricultural importance, a wealth of functional
genomics informationhas been established in this species. This provides a
rich background of existing data for interpretation of new results
generated in genomics studies using domestic pig breeds or minipigs.
Several characteristics of the pig combine to facilitate identiﬁca-
tion of the genetic basis of phenotypic traits. The phenotypic diversity
within pig breeds, together with breeding history and population
structure, offer unique advantages for the molecular dissection of
multifactorial traits. In only a few thousand years, selective breeding
has produced pig breeds that thrive in diverse environments and
climatic conditions, convert energy to muscle mass efﬁciently and
rapidly, and tolerate speciﬁc pathogens. Since the effective population
size is smaller than that of humans the genetic complexity of the traits
will in most cases be reduced. Furthermore, since population-wide
linkage disequilibrium (LD) in livestock extends over tens of
centimorgans (rather than subcentimorgan regions as typically
observed in humans), locating genetic determinants is considerably
easier in the pig compared toman. Inmany respects, breeds of pigs are
similar to human ethnic groups with diverse geographic origins, but
with more exaggerated phenotypic diversity.
Finally, there can be little doubt that the understanding of the
factors that make porcine breeds differ with respect to reproductive
efﬁciency, bone structure, growth rates, fat deposition, and resistance
to speciﬁc pathogens will be important to understanding basic
biological processes important to human health. The general
advancement of genomics together with the favourable character-
istics of the species, suggest that progress could be rapid.
2.2. Relevance of pig genomic data formanand humanbiomedical research
Although less close to man in evolutionary terms than non-human
primates, the pig is generally considered a good model in biomedical
researchbecause of its anatomical andphysiological similarity tohumans
with respect to a variety of organs and functions. A recent phylogenetic
study based on rare genomic changes has clusteredprimates and rodents
together (Murphy, Pringle, Crider, Springer and Miller, 2007). However,
while it has taken many short (evolutionary) branchings to reach the
present day rodents, the branches leading to both humans and pigs are
much shorter (Springer, Murphy, Eizirik & O'Brien, 2003). It is important
to keep in mind that the differences between DNA sequences of two
species are not solely a function of the elapsed time since their
divergence. It has recently been shown that the evolutionary distancein sequence space between the porcine and human genome sequences is
smaller than thedistance betweenmouse andhuman (Grønlund,Hobolt,
Hornshøj, Bendixen, Fredholm & Schierup, 2005; Wernersson, Schierup,
Gorodkin, Panitz, Jun, Stærfeldt et al., 2005). These studies are based on
comparison of human, mouse and pig full length cDNA alignments
comprising more than 700,000 nucleotides and approximately 0.7×
coverage from the pig genome respectively.
The Göttingenminipig is predisposed to obesity, unlike production
pigs which have been strongly selected for low fat content and
leanness. Thus, backcrossing and intercrossing minipigs with produc-
tion pigs will provide ideal families for identiﬁcation of genes involved
in obesity, since it can be predicted that the traits and genes involved
in obesity will segregate. Genes underlying other traits that differ
between the two breeds (e.g. size, growth, age of sexual maturity) will
also segregate in the crossbred animals. This is therefore an
interesting model with great potential to generate knowledge about
the molecular basis of range of different traits.
3. Toxicogenomics
Toxicogenomics is the study of gene expression modulation after
exposure to a test item with the objective of gaining a deeper
mechanistic understanding of toxic actions, and developing predictive
tools to rank, select and evaluate new drugs and chemicals. Genome-
based technologies such as DNA microarrays allow the simultaneous
analysis of the expression of many thousands of genes in a single
experiment. Whole genome microarrays are available for several
species, including humans and laboratory animal species routinely
used in safety evaluation such as the rat, mouse, primate and also the
pig. The study of thousands of parameters in a single sample can give
new insights into the assessment of the effects which a chemical or
drug can cause, whether beneﬁcial (pharmacology or efﬁcacy) or
harmful (toxic). Drug induced changes in the regulation of gene
expression can occur within few hours after drug exposure. This
opens the way for the deployment of short term toxicogenomics
studies in different ways and toxicogenomics approaches can provide:
– A basis for compound classiﬁcation: compounds with the same
pharmacological or toxic mechanism of action generate similar
changes in gene expression proﬁles,
– A better understanding of toxicological mechanisms through the
study of the function of the genes that are modulated by a drug
treatment, as well as the signalling pathways or ontologies in
which proteins encoded by these modulated genes are classiﬁed.
– The discovery of new pharmacological/efﬁcacy/toxicity biomar-
kers: consistently regulated genes across several compound time/
dose combinations may be good candidates as markers for drug
effects,
– The generation of toxicity signature databases, by correlating the
early gene expression proﬁles induced by reference compounds
with traditional toxicology endpoints such as histopathology or
clinical pathology ﬁndings. These toxicity signature databases can
be composed of several tens of genes and are built by taking out
the genes that are regulated in common by several drugs that
produce the same toxicological phenotype.
– The early prediction of new compound toxicity by transcriptional
proﬁle comparisons with existing (in-house or commercially
available) toxicity signature databases.
– The discovery of new pharmacological actions of existing drugs,
permitting the repositioning of these drugs for new therapeutic
indications.
3.1. Gene expression and toxicogenomics studies in the pig
Toxicogenomics studies need up-to date genome annotation
databases in order to mine the huge amount of data generated by
230 R. Forster et al. / Journal of Pharmacological and Toxicological Methods 62 (2010) 227–235microarray technologies and to derive mechanistic information. The
integration of structural (i.e., genetic) and functional data is also very
useful in order to understand the individual variability in the gene
expression proﬁles generated by a treatment. The context for gene
expression studies in the pig is very favourable since much annotation
data is available from mapping exercises together with functional
information on genes (as described above). This is demonstrated by the
results of a rapid bibliographic comparison using PubMed:
b“expressed sequence tags” and ratN yielded 485 results
b“expressed sequence tags” and porcineN yielded 144 results
b“expressed sequence tags” and canineN yielded 38 results
b“expressed sequence tags” and “non human primate”N yielded 14
results
Compared with the dog and the monkey, non-rodent laboratory
species typically used in toxicology and safety evaluation, a signiﬁ-
cantly greater volume of genomic work is being performed in the pig.
The number of available porcine ESTs has greatly expanded in the
last ﬁve years, andmore than onemillion porcine ESTs have now been
deposited in theNCBI GenBank (Gorodkin et al, 2007). Recent progress
in the porcine sequencing project, as well as porcine genome
annotation, has improved the identiﬁcation of differentially expressed
genes in experiments using Serial Analysis Gene Expression (SAGE),
Differential Display or Subtractive Hybridization approaches (i.e., non-
microarray approaches). Academic groups have used these technol-
ogies in order to understand the molecular mechanisms involved in
pig livestock improvement, such as muscle growth and development
(Janzen, Kuhlers, Jungst & Louis, 2000) or the response to infection
(Wang, Hawken, Larson, Zhang, Alexander & Rutherford, 2001).
Several academic and/or industrial laboratories have also devel-
oped custom porcine microarrays using these ESTs. Transcriptomics
studies have been performed, principally aimed at livestock improve-
ment, and dealing with muscle development (see Kim, Chang, Hong,
Jung, Kwon, Cho et al., 2005), reproduction (Whitworth, Agca, Kim,
Patel, Springer, Bivens et al., 2005) and infection (Moser, Reverter,
Kerr, Beh & Lehnert, 2004).
Porcine microarray chips are available commercially (Affymetrix
GeneChip® Porcine Genome Array, interrogating approximatively
23,256 transcripts from 20,201 S. scrofa genes). Operon Biotechnol-
ogies has developed a set of 13,297 annotated “ready to spot”
oligonucleotides speciﬁc for S. scrofa. These DNA fragments can be
used to manufacture DNA chips for pig transcriptomics studies, which
can be used for the generation of reliable toxicogenomics and/or
pharmacology data in minipigs.
Nevertheless, it appears that very little gene expression work has
been done in pigs in the context of toxicology and safety assessment.
The principal animal models used for toxicogenomics studies and
predictive toxicology are rats, reﬂecting the predominant position of
the rat in regulatory toxicology. Several companies (including Iconix
and Gene Logic) have developed toxicity signature databases by
correlating the early gene expression proﬁles induced by reference
compounds in key target tissues of the rat (liver, kidney and heart)
with traditional toxicology endpoints such as histopathology or
clinical pathology ﬁndings.
Unpublished and conﬁdential studies performed by pharmaceuti-
cal companies and CRO's will also constitute a signiﬁcant proportion
of the work in this area. Here also we anticipate that the rat and the
non-human primate will be the principal models used in toxicoge-
nomics studies.
The potential advantages of the pig in the area of toxicogenomics
remain unexploited at the present time. As for other animal models,
we may expect that the application of toxicogenomic approaches to
the pig and to the minipig will lead to valuable insights and the
identiﬁcation of useful efﬁcacy and/or toxicity biomarkers.3.2. Porcine genomics and toxicogenomics: technical gaps
No signiﬁcant technical gaps were identiﬁed in terms of genomics
tools that could potentiate the role of the pig (or minipig) in
toxicogenomic investigations. The principal technical issue impeding
the wider application of genomics and related technologies to the
minipig is the deﬁcit in the bioinformatics infrastructures for storage,
analysis and use of the porcine gene expression data (both data
already available and that which will be generated in the future). This
is not an issue speciﬁc to porcine genomics, and the comment is
equally applicable to the development of genomics studies in other
animal species.
Data mining in transcriptomics studies relies on existing annota-
tion as well as expression databases. Predictive toxicology studies
particularly need the comparison of transcription proﬁles with drug
signature databases. Up to now, no such database for the pig and/or
minipig has been generated and this leaves a very important gap in the
development of genomics tools for predictive toxicity and/or phar-
macology studies. The value of the minipig as a model in toxicoge-
nomicswould be greatly enhanced by availability of toxicity databases
and validated toxicity signatures (on the model of the Gene Logic and
Iconix databases for the rat, described above). Initiatives in this area,
through collaborative exercises, or through private or public funding,
could have a signiﬁcant catalysing role in the use of the minipig as a
model for toxicogenomic studies, and hence permit the toxicology
community to beneﬁt from the strong pre-existing genomics knowl-
edge base for the pig.
Initiatives are needed to open up data generated in livestock
context for exploitation in other areas of research such as safety
assessment. Genomics studies in livestock context provide new
information concerning gene functions that may also provide insights
in the ﬁeld of safety assessment. The generation of focused databases
should be encouraged.
3.3. Genomics and toxicogenomics: conclusions
Much research in the animal breeding, genetics and genomics of the
pig has been undertaken, driven largely by the economic and
agricultural importance of the pig. As a consequence the genomics
knowledge base for the pig is strong, and the tools and databases
required to facilitate pig genomics studies are well developed. These
tools and the genomic data generated for the domestic pig are equally
relevant and applicable to different pig breeds including minipigs. The
context for gene expression and toxicogenomics studies in the pig is
therefore very favourable. We anticipate that this general conclusion is
also true for the application of other –omics technologies such as
proteomics and metabolonomics. Nevertheless, it appears that very
little gene expression work has been done in pigs in the context of
toxicology and safety assessment and the potential advantages of the
pig in the area of toxicogenomics remain unexploited at the present
time. Initiatives to make available toxicity databases and validated
toxicity signatures could have a signiﬁcant catalysing role in the use of
the minipig as a model for toxicogenomic studies.
The pig genome shows extensive homology with the human
genome and evidence from sequence studies suggest that the
evolutionary distance in sequence space between the porcine and
human genome sequences is smaller than the distance between
mouse and human (and by implication, probably also the rat and the
human).
4. Genetic manipulation in the pig
4.1. Introduction
The ability to add or remove genetic material from the germline of
mammals has been possible since the late 1970s. Such genetically
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addition to transgenic mice, gene transfer technology has enabled the
generation of transgenic rats, sheep, goats, cattle and pigs. There are two
reports of transgenic monkeys (Chan, Chong, Martinovich, Simerly &
Schatten, 2001; Sasaki, Suemizu, Shimada, Hanazawa, Oiwa, Kamioka
et al., 2009) and there are no reports of transgenic dogs. Transgenic
minipigs have been generated (Uchida, Shimatsu, Onoe, Matsuyama,
Niki, Ikeda et al., 2001) and arguments presented for their use in
biomedical research (Vodicka, Smetana, Dyorankova, Emerick, Xu,
Ourednik et al., 2005).
Although the vast majority of transgenic work has been performed
in the mouse, much of the transgenic technology established in this
species is applicable to large animal species such as the pig, dog and
monkey. However, differences in the reproductive processes in each
species and the extent of understanding of their reproductive
physiology, results in signiﬁcant differences in the ability to generate
transgenic models in these different species.
4.2. Gene transfer methods in the pig
A variety of transgene delivery methods have been established for
the generation of genetically modiﬁed animals (Clark & Whitelaw,
2003). All were initially developed in mice and subsequently applied
to larger animal species.
The original method of transgene delivery involves the direct
(micro)-injection of DNA into the pronuclei of fertilised eggs. This
method has been applied to pigs for the last two decades. Although
this method is less efﬁcient in the pig than in the mouse, pronuclear
injection still enables the robust generation of transgenic pigs (Brem&
Springmann, 1989; Clark &Whitelaw, 2003). Recently amore efﬁcient
transgene delivery route has been established, involving the use of
replication-defective lentivirus vectors (Whitelaw, 2004). This meth-
od is at least 10-fold more efﬁcient than pronuclear injection when
assessed in terms of the number of transgenic founder (F0) animals,
and has been used to generate transgenic pig models (Hofmann,
Kessler, Ewerling, Weppert, Vogg, Ludwig et al., 2003; Whitelaw,
Radcliffe, Ritchie, Carlisle, Ellard, Pena et al., 2004). The increased
efﬁciency can be expected to result in an overall reduction in the
number of animals needed to generate a transgenic pig model.
In themouse, gene transfer canbe achievedusing cultured embryonic
stem (ES) cells which can be genetically modiﬁed prior to introduction
into mouse embryos. This approach permits targeted genetic modiﬁca-
tions by homologous recombination. Unfortunately equivalent ES cell
lines do not currently exist for pigs or dogs (Clark &Whitelaw, 2003) and
ES cell technology cannot be applied to these species.
Recent work by groups in Japan and the US has pioneered the way to
reprogram somatic cells, such as ﬁbroblasts, to become pluripotent. This
involves as yet unknown signalling cascades through the simple
transfection of four genes—myc, sox2, klf4 and Oct4. In this way somatic
cells are reprogrammed to become ES-cell like in nature and action,
designated induced Pluripotent Stem cells (iPS). This has been
demonstrated for mouse ﬁbroblasts and more recently for human cells
(Takahashi, Tanabe, Ohnuki, Nariat, Ischisaka, Tomoda et al., 2007), thus
opening up the possibility that the 4-gene approachmay be applicable to
a range of animal species, which is clearly a stimulating proposition.
Concurrently, primate ES cells have been generated using a nuclear
transfer technique (Byrne, Pedersen, Clepper,Nelson, Sanger et al., 2007).
In the absence of ES approaches for pigs and dogs, gene targeting in
these non-rodent species can be achieved using nuclear transfer
(cloning) technology (Wilmut, Schnieke, McWhir, Kind & Campbell,
1996), since the donor cell can be genetically modiﬁed prior to
transfer. Several transgenic pigmodels have been produced in thisway
(Vajta, Zhang &Machaty, 2007). This method allows for gene deletion
(and thus removal of gene activity) and is currently being utilised in
the development of animals for xenotransplantation studies (Bucher,
Morel & Bucher, 2005).Building on the initial and highly debated claims of sperm-
mediated gene transfer (Wall, 1999), intracytoplasmic sperm injec-
tion using transgenic sperm cells has emerged as an alternative
transgene delivery route and has been recently demonstrated in pigs
(Yong, Hao, Lai, Li, Murphy, Rieke et al., 2006). The emergence of
spermatogonial stem cell culture (Kanatsu-Shinohara, Ikawa, Takeha-
shi, Ogonuki, Miki, Inoue et al., 2006) may further contribute to this
approach by facilitating the ability to introduce transgenes into the
donor cells.
Looking to the future, it is anticipated that the recent trend to
develop more precise and efﬁcient transgene delivery methods will
continue to have a positive impact in terms of the 3R's. Given the state
of knowledge of reproductive processes and technical capabilities in
embryology manipulation it is likely that transgenesis in the pig will
remain more advanced than transgenesis in the monkey and dog.
4.3. Transgenic animals and reproductive technologies in toxicology
In the 25 years since the ﬁrst production of a transgenic mouse by
Gordon and Ruddle in 1981, transgenic approaches have already
begun to play a signiﬁcant role in regulatory toxicology. One
established area of use of transgenic mice is in short-term tests for
carcinogenic properties. After a large scale collaborative study to
evaluate the use of four carcinogenesis-prone transgenic mouse
strains in the testing of newmedicines, these model are now accepted
by regulatory authorities as part of the “weight-of-evidence” evalu-
ation of carcinogenic properties (Jacobson-Kram, Sistare & Jacobs,
2004). Transgenic mice also increasingly ﬁnd a role in routine
toxicology testing of biotechnology products, in those cases where
themolecular targets of biologicals are only present in humans and are
not present in laboratory animals. In such cases, genetic modiﬁcation
may offer a route to develop an appropriate model for toxicology
testing, where otherwise no appropriatemodel exists (Ma& Lu, 2007).
Another potentially valuable area of application is the use of transgenic
strains with modiﬁed metabolic capabilities, including hepatic
cytochrome P450 reductase null mice (Henderson & Wolf, 2003).
Numerous further applications may be proposed: transgenic reporter
animals that enable sensitive and rapid read-out of toxic insults could
contribute to early toxicity screens (Maggi, Ottobrini, Biserni,
Lucignani & Ciana, 2004), and reporter systems enabling non-invasive
and/or real time read-out are being developed.
At present these approaches have not been extended to include
transgenic non-rodent approaches in toxicology, but in principle there
is no reason why current transgenesis approaches could not also be
applied to dogs and monkeys. In the case of the dog and the monkey,
limitations are entirely technical and transgenic models are not
generated in these species on a routine basis. Our knowledge of early
reproductive processes in the dog is limited (Luvoni, Chigioni &
Beccaglia, 2006), resulting in a lack of technical know-how for
manipulation of the dog embryo. There is one report of a transgenic
macaque monkey (Chan et al, 2001) and one report of a transgenic
New World monkey, generated (Sasaki et al., 2009); both were
generated using viral vector transgène delivery approaches. Although
techniques for monkey species are not currently well-established in
the laboratory, it is anticipated that methods to manipulate monkey
embryos could be readily developed, building on our extensive
knowledge of human embryonic development.
In contrast transgenic pigs have been generated for the last two
decades and all the required procedures are now well established
(Pursel, Pinkert,Miller, Bolt, Campbell et al., 1989;Golovan,Meidinger,
Ajakaiye, Cotrill, Wiederkehr et al., 2001; Lavitrano, Bacci, Forni,
Lazzereschi, Di Stefano et al., 2002; Whitelaw et al 2004; Kraft, Allen,
Petters, Hao, Peng &Wong, 2005; Kues, Schwinzer, Wirth, Verhoeyen,
Lemme et al., 2006; Deppenmeier, Bock, Mengel, Niemann, Kues et al.,
2006; Hao, Yong,Murphy,Wax, Samuel et al., 2006). These approaches
have also been applied to minipigs and transgenic minipigs have been
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transgenic minipigs using nuclear transfer of transgenic donor cells
(Gabor Vajta, personal communication). It seems very likely that
techniques for transgenesis in the pigwill remainmore advanced than
those for themonkey anddog in coming years. Themomentmay arrive
in the future, where new technologies and new approaches in
toxicology may in the future lead us to expect signiﬁcant ethical and
technical beneﬁts through the development of transgenic non-rodent
models (for example, through the generation of sensitive “reporter”
models with non-invasive read-out of genomic responses). In these
cases, our current knowledge base and experience indicates that the
pig will be the species of choice.
4.4. Genetic manipulation in the pig: conclusions
In conclusion, transgenic germline manipulation is established and
well developed in pigs and there are numerous examples of transgenic
pigs, including transgenicminipigs. In contrast these approachedarenot
well established in monkeys or dogs at the present time. A key tool in
this area is theES cell. Currently ESor ES-like cells only exist formiceand
man. There are currently a number of experimental avenues being
explored that lead to the generation of pluripotent cells and it is a
realistic expectation that ES based approaches will be developed for
other species beyondmiceandman.Of thenon-rodent species routinely
used in regulatory toxicology testing (dog, minipig, monkey), the pig is
the only species in which the generation of transgenic models is well
established. This represents a real advantage for the testing of those
biotechnology products which are highly species-restricted and for
which no appropriate animalmodel exists, permitting the development
of transgenic models for toxicology testing.
5. Cloning and reproductive technologies in the pig
5.1. Cloning in the pig
The term “cloning” refers to somatic cell nuclear transfer (SCNT)
technology, which permits the generation of genetically identical
“cloned” animals. The development of cloning technology (Wilmut et
al, 1996) and the attendant publicity given to “Dolly” and other cloned
animals has had an enormous impact on the public perception of
research in this area, and led to widespread public debate of the ethical
issues and ﬁnally the need for legislative processes (Suk, Bruce, Gertz,
Warkup, Whitelaw, Braun et al., 2007). Cloning can be combined with
genetic modiﬁcation (transgenesis) but, without the use of genetically
modiﬁed cells, represents replication of genetically identical animals.
This canbeviewedas analogous tonormal reproductive processesduring
twinning (Fulka&Fulka, 2007).Unlike twinning,multiple clonedanimals
may be produced and cloning thus enables the generation of populations
of genetically identical animals. Thismay also be achieved by inbreeding,
but with attendant disadvantages resulting from consanguinity.
Numerous studies demonstrate the application of nuclear transfer
cloning in pigs (Vajta et al, 2007, Pursel et al 1989; Kues et al 2006;
Deppenmeier et al 2006) and recent efforts have resulted in the
generation of transgenic minipigs using this technology (Kragh,
Nielsen, Li, Du, Lin, Schmidt et al., 2009). The ﬁrst report of cloning
in dogs was surrounded by controversy but is now considered to be
factual (Parker, Kruglyak & Ostrander, 2006; Luvoni et al, 2006).
Cloned monkeys have been generated (Meng, Ely, Stouffer & Wolf,
1997) but the various difﬁculties encountered in producing non-
human primate embryos by nuclear transfer indicate that cloning
technology is still only poorly established for monkeys (Simerly,
Navara, Hyun, Lee, Kang, Campuano et al., 2004). Nuclear transfer
cloning cannot currently be considered to be routine in either dogs or
monkeys. In contrast, cloning is well established in pigs and it is
expected that this approach can easily be applied also to minipigs.Cloning is potentially of interest in the development of animal
models, since identical individuals can be generated without the
accompanying disadvantages of consanguinity. This could potentially
offer reduced animal to animal variability within groups of animals,
and possibly provide opportunities for the experimental reﬁnement
and reduction in animal numbers.
5.2. Reproductive biotechnologies in the pig
Beyond cloning, several other reproductive biotechnologies im-
pact on the possible use of animals in toxicology. Such technologies
focus on the earlymammalian embryo and include in vitro fertilisation
(IVF) and in vitro maturation (IVM), embryo splitting and twinning.
The ability to perform IVF/IVM enables the use of surplus eggs (e.g.
from a slaughterhouse). In contrast, for species where these technol-
ogies are not established, embryo manipulation requires in vivo
fertilised embryos, probably after super-ovulation of the donor females.
IVM/IVF capability is therefore associated with reduced animal
numbers, reduced animal welfare concerns and reduced ﬁnancial costs.
In the pig, despite considerable progress, IVM/IVF systems are still
not optimal (Nagai, Funahashi, Yoshioka & Kikuchi, 2006). For the
generation of transgenic pigs the lack of IVM/ICF capability can be
offset by efﬁcient transgene delivery systems, such as that offered by
lentivirus vectors (Whitelaw et al, 2004; Sasaki et al, 2009). Currently
for dogs the situation is even less favourable, principally due to our
limited understanding of the necessary conditions for successful in
vitro development of dog embryos (Luvoni et al, 2006). Building on
the extensive human clinical use of IVF/IVM, procedures for these
technologies in monkey are established (Yin, Duffy & Gosden, 2006).
The advantage of twinning is that genetically identical paired
animals are generated. Embryo splitting and the generation of twins is
not robust in monkeys (Schramm & Paprocki, 2004), and not at all
practiced in the dog. In contrast, embryo splitting has been established
for the pig for some time (Nagashima, Katoh, Shibata & Ogawa, 1988).
5.3. Cloning and reproductive biotechnologies: conclusions
In conclusion, nuclear transfer cloning and most other reproduc-
tive biotechnologies are well established in the pig, some approaches
are developed for primates and very few have been applied to dogs. As
a consequence a number of technical possibilities are available in the
pig (and minipig) making this species an attractive research model.
IVM/IVF systems are still not optimal in the pig, and there would be
animal welfare beneﬁts if progress could be made in this area. Overall
the pig is well positioned for future developments in cloning and
reproductive biology.
6. Biosensors and nanotechnologies
A range of “sensor” technologies could contribute in important
ways to the way that toxicology is performed in the future.
Developments in telemetry, remote sensors, biosensors, automated
sampling and imaging have the potential to enrich the data obtained
from animals used in regulatory toxicology studies. These approaches
may replace some invasive techniques or techniques requiring
sacriﬁce, and may allow in vivo monitoring and serial recording of
physiological parameters and relevant toxicology biomarkers and/or
biomarker signatures.
Biosensor readouts of this kind could permit investigators to obtain
more extensive data from large animals both in terms of the range of
endpoints/parameters that are measured, and in terms of the time
points since continuous monitoring may be possible. Approaches of
this kind may also permit reductions in the numbers of rodents (and
satellite animals) that are required for the performance of studies. It is
clear, therefore, that such approaches have clear implications for the
application of the 3Rs in regulatory toxicology.
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implanted devices, telemetry, cannulation, or analyses performed on
using blood and urine samples, skin punches, biopsies etc. Other
approaches are non-invasive, such as sensor patches, intracorporeal
nanotechnology remote readout sensors and transgenic reporter genes
(such as luciferase, green ﬂuorescence proteins, urinary excreted
reporters).
This is a fast moving area of research and it is not easy to accurately
deﬁne what will become available or when these new technologies
will result in useful applications. It was nevertheless the consensus
opinion of the authors that these technologies can be expected to be
neutral in terms of selection of animal models, and do not favour the
use of any particular large animal species.
7. In vitro alternatives in toxicology testing
Given the swell of academic interest that has centred on in vitro
alternatives in toxicology testing, and the generous funding that has been
made available in this area, we can look forward to progress and new
developments in the replacement of animal studies in coming years. In
vitro tests have already met with some success in the replacement of
animal studies that address a single well-deﬁned endpoint (for example,
skin irritation, skin corrosion, endotoxin detection, mutagenic activity
etc.). For the time being, in vitro approaches have not been developed
which canaddress issuesof “general toxicity”,where the targetorganand
possible harmful effects of a drug remain undeﬁned. In the future,
approaches may also be developed for this more complex problem,
perhaps through the application of toxicogenomics.
Sources of tissues or cells (primary cells or permanent cell lines)
are generally required for in vitro assay systems. Since the objective in
regulatory toxicology is the prediction of hazard for humans, it will
normally be most relevant to use human tissues and cells where they
are available. There are cases where complex (genetic) manipulations
have been performed on the biological test materials, or cell lines are
used which have very speciﬁc phenotypes and characteristics, but
apart from such cases, why not use human material if you can!
Some human tissues are hard to obtain, especially those tissues
that are in high demand for transplantation, and there may be other
circumstances where it is impractical to work with material of human
origin. Where this is so, researchers should consider the close
anatomical, physiological and biochemical similarities between pigs
and humans. On account of these similarities, pigs may often be the
most appropriate choice of species for the derivation of cells, and may
provide the best prediction of human hazard.
A furtherpractical advantageof thepig asa sourceof tissues andcells is
that domestic pig materials may be readily available from the slaughter-
house, while it will be necessary to sacriﬁce animals in order to obtain
tissues from non-food source animal species (e.g., monkey hepatocytes).
In conclusion, therefore, it was considered that, generally speaking,
human tissues and cells will be the most appropriate biological
material for in vitro tests intended to predict a hazard for humans.
Where human material cannot be used, careful consideration should
be given to the pig as a source of tissues and cells. Because of the close
anatomical, physiological and biochemical similarities between pigs
and humans, the use of pig materials may often provide the best
prediction of a hazard for man. A further practical advantage is that
porcine material can be readily obtained from the slaughterhouse,
while non-food source species must be sacriﬁced to provide tissues.
8. Conclusions and recommendations
8.1. Gaps and opportunities
This article has identiﬁed many potential opportunities for further
research. Of these opportunities there are 3 that deserve particular
mention1. Breed minipigs for smoother temperament: Anybody who has
worked with Göttingen minipigs will attest that they are not always
easy to handle. The opportunity therefore exists to selectively breed
minipigs for smoother temperament and greater tolerance of human
contact.Much in the sameway that reducedbodysize and “dominant
white” skin colour of the Göttingen minipig were intended to adapt
theminipig to laboratoryuse, breeding for temperamentwould bring
further beneﬁts in the laboratory environment. Better tolerance of
human contact and greater amenability to handling would at the
same time reduce the stress to animal handlers and scientiﬁc staff
and also reduce the stress for the animals themselves. In consequence
this would be a highly ethical development reducing anxiety during
laboratory manipulation for both animal handling staff and for the
minipigs and certainly contributing to enhancing the scientiﬁc
quality of the work performed
2. Data baseof drug-induced geneexpression signatures in theminipig:
Mini-pigs are very well positioned for use in toxicogenomic studies.
Established experience in toxicogenomics studies would clearly
favour the use of theminipig in routine regulatory toxicology studies,
because of the additional interpretative data andmechanistic insight
that it can bring. Data on the gene expression changes and signatures
after treatment with reference toxicants would be very valuable in
this respect, establishing themini-pig as a toxicogenomicsmodel and
stimulating its further use. Predictive toxicology studies particularly
need the comparison of transcription proﬁles with drug signature
databases. Up to now, no suchdatabase for thepig and/orminipig has
been generated and this leaves a very important gap in the
development of genomics tools for predictive toxicity and/or
pharmacology studies. The value of the minipig as a model in
toxicogenomicswould be greatly enhanced by availability of toxicity
databases and validated toxicity signatures.
3. Progress in reproductive biology: further understanding of the
reproductive biology of the pig/minipig focused on reﬁnement of
IVM/IVF techniques would bring animal welfare beneﬁts. In
particular it could permit the use of slaughterhouse-derived
oocytes for embryo manipulation and genetic modiﬁcation work,
with a corresponding positive impact on the reduction of animal
numbers used for experimental work
8.2. Application of 3Rs
This article describes a number of opportunities for 3R's beneﬁts
through technologies that can provide a greater volume ofmore relevant
data from a smaller number of animals, or from the development of
animal models that are more pertinent for the evaluation of safety.
The targeted breeding of minipigs for smoother temperament and
better tolerance of human contact would be a highly ethical project. It
would result in reduced stress and anxiety during laboratory
manipulations for both animal handling staff and for the minipigs
themselves and would certainly contribute to enhancing the scientiﬁc
quality of the work performed.
8.3. Conclusions
In reviewing the potential of the minipig as a platform for future
developments in genomics, high density biology, transgenic technol-
ogy, in vitro toxicology and related emerging technologies, a number
of features and advantages of this model emerge.
First, it is a repeated theme of this article that commercial interests
in the pig as an agricultural production species have driven scientiﬁc
progress in several research areas. There is no equivalent economic
driver for progress in the dog or the monkey. As a result the available
knowledge-bases are much greater for pigs (than for dogs or
monkeys) in many areas (physiology, disease, genetics, immunology
etc). Fundamental genomic knowledge and phenotypic characteriza-
tion in regard to the pig is well in advance of the dog or the monkey
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other two species.
In the ﬁeld of genomics a range of genomic tools is available
including sequence data, SNP chips and whole genome arrays. These
tools and the genomic data generated for the domestic pig are equally
relevant and applicable to different pig breeds includingminipigs. The
context is propitious for studies in functional genomics and for the
identiﬁcation of genetic mechanisms associated with gene functions
and genotypes. All the elements are in place for the exploitation of the
pig in toxicogenomics. Nevertheless, it appears that very little gene
expression work has been done in pigs in the context of toxicology
and safety assessment and the potential advantages of the pig in the
area of toxicogenomics remain unexploited at the present time.
Initiatives to make available toxicity databases and validated toxicity
signatures could have a signiﬁcant catalysing role in the use of the
minipig as a model for toxicogenomic studies.
The pig genome shows extensive homology with the human
genome and evidence from sequence studies suggest that the
evolutionary distance in sequence space between the porcine and
human genome sequences is smaller than the distance between
mouse and human (and by implication, probably also the rat and the
human). These sequence similarities suggest that the molecular
targets of the pig may conserve homology with human targets and
that the minipig may ﬁnd a role in the testing of biotechnology
products. In the same way, the sequence similarity suggests that the
minipig could play a leading role in approaches to in silico toxicology.
When we turn to genetic manipulation and reproductive technol-
ogies, transgenic germline manipulation is well established in pigs
and there are numerous examples of transgenic pigs, including
transgenic minipigs. In contrast these approached are not well
established in monkeys or dogs at the present time. Of the non-
rodent species routinely used in regulatory toxicology testing (dog,
minipig, monkey), the pig is the only species in which the generation
of transgenic models is well established. The ability to generate
transgenic minipig models represents a real advantage for the testing
of highly species-restricted biotechnology products. For such pro-
ducts, cases are often encountered where no relevant animal model
exists, and the development of transgenic models is necessary in
order to generate relevant animal models and permit safety testing.
Nuclear transfer cloning and most other reproductive biotechnol-
ogies are well established in the pig, some approaches are developed
for primates and very few have been applied to dogs. Overall the pig is
well positioned for future developments in cloning and reproductive
biology.
In addition to the strong position of theminipig in genomics and in
germline manipulation, it must also be remembered that the
Göttingen minipig is a genetically managed model (unlike routinely
used dog and monkey toxicology models), and that the basis of the
small size of the Göttingen minipig does not involve defective genes.
While the emerging technologies are essentially “species neutral”
and can in principle be applied to all species, for all the technologies
that we examined, basic knowledge and technical capabilities are
greater for the pig than the dog or monkey. In concrete terms, in
application to safety testing we have seen that:
– The Göttingen minipig is well positioned for the performance of
toxicogenomics studies.
– The sequence homology between pigs and humans suggest that
minipigs will be useful for the testing of biotechnology products
(and possibly for in silico toxicology).
– And ﬁnally the minipig is the only non-rodent toxicology model
where transgenic animals can be readily generated, and repro-
ductive technologies are well developed in the pig.
These factors all support the idea that the minipig is well placed to
meet the challenges of the emerging technologies and the toxicology
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